Sigyn Therapeutics, Inc. (SIGY)
USD 3.15
(0.0%)
USD 3.15
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.45 Million USD | -14.35% |
| 2022 | -2.14 Million USD | -6.92% |
| 2021 | -2 Million USD | -119.13% |
| 2020 | -916.43 Thousand USD | -76.93% |
| 2019 | -517.95 Thousand USD | 48.45% |
| 2018 | -1 Million USD | 58.73% |
| 2017 | -2.43 Million USD | -242.76% |
| 2016 | -710.2 Thousand USD | 68.48% |
| 2015 | -2.25 Million USD | -481.39% |
| 2014 | -387.54 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -629.97 Thousand USD | 12.17% |
| 2024 Q2 | -602.8 Thousand USD | 4.31% |
| 2023 Q2 | -574 Thousand USD | -10.12% |
| 2023 Q1 | -521.25 Thousand USD | -10.53% |
| 2023 FY | -2.45 Million USD | -14.35% |
| 2023 Q4 | -717.23 Thousand USD | -11.58% |
| 2023 Q3 | -642.81 Thousand USD | -11.99% |
| 2022 Q3 | -533.64 Thousand USD | -0.16% |
| 2022 Q4 | -471.58 Thousand USD | 11.63% |
| 2022 FY | -2.14 Million USD | -6.92% |
| 2022 Q1 | -609.23 Thousand USD | -3.1% |
| 2022 Q2 | -532.79 Thousand USD | 12.55% |
| 2021 FY | -2 Million USD | -119.13% |
| 2021 Q3 | -573.36 Thousand USD | -29.77% |
| 2021 Q1 | -402.09 Thousand USD | 41.2% |
| 2021 Q2 | -441.81 Thousand USD | -9.88% |
| 2021 Q4 | -590.93 Thousand USD | -3.07% |
| 2020 FY | -916.43 Thousand USD | -76.93% |
| 2020 Q1 | -90.43 Thousand USD | 27.69% |
| 2020 Q3 | -87.57 Thousand USD | -60.52% |
| 2020 Q2 | -54.56 Thousand USD | 39.67% |
| 2020 Q4 | -683.86 Thousand USD | -680.87% |
| 2019 Q2 | -101.31 Thousand USD | 40.0% |
| 2019 Q1 | -168.85 Thousand USD | -347.56% |
| 2019 FY | -517.95 Thousand USD | 48.45% |
| 2019 Q4 | -125.06 Thousand USD | -1.9% |
| 2019 Q3 | -122.72 Thousand USD | -21.13% |
| 2018 Q3 | -268.75 Thousand USD | 30.87% |
| 2018 Q4 | 68.2 Thousand USD | 125.38% |
| 2018 Q1 | -415.38 Thousand USD | 53.72% |
| 2018 Q2 | -388.74 Thousand USD | 6.41% |
| 2018 FY | -1 Million USD | 58.73% |
| 2017 Q2 | -615.32 Thousand USD | -78.79% |
| 2017 FY | -2.43 Million USD | -242.76% |
| 2017 Q4 | -897.63 Thousand USD | -54.71% |
| 2017 Q3 | -580.21 Thousand USD | 5.71% |
| 2017 Q1 | -344.16 Thousand USD | -140.56% |
| 2016 Q4 | 848.55 Thousand USD | 357.57% |
| 2016 Q3 | -329.44 Thousand USD | 37.47% |
| 2016 Q1 | -712.67 Thousand USD | 12.23% |
| 2016 Q2 | -526.88 Thousand USD | 26.07% |
| 2016 FY | -710.2 Thousand USD | 68.48% |
| 2015 Q1 | -151.79 Thousand USD | -7.89% |
| 2015 Q4 | -811.95 Thousand USD | 0.56% |
| 2015 FY | -2.25 Million USD | -481.39% |
| 2015 Q3 | -816.55 Thousand USD | -68.97% |
| 2015 Q2 | -483.26 Thousand USD | -218.36% |
| 2014 Q3 | -78.32 Thousand USD | 0.0% |
| 2014 FY | -387.54 Thousand USD | 0.0% |
| 2014 Q4 | -140.7 Thousand USD | -79.63% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | -1642.509% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -257.423% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1331.592% |
| CytoDyn Inc. | -18.05 Million USD | 86.403% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 95.838% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -339590.513% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -35.181% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 51.327% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -8097.506% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1252.904% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 74.702% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 95.577% |
| SQZ Biotechnologies Company | -75.82 Million USD | 96.762% |
| Resverlogix Corp. | -12.74 Million USD | 80.741% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -530.263% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 125.202% |
| Mesoblast Limited | -84.14 Million USD | 97.082% |
| GB Sciences, Inc. | -1.42 Million USD | -72.848% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -257.423% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 86.242% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 27.89% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 63.067% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 22.503% |
| ContraFect Corporation | -56.88 Million USD | 95.684% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 10.743% |
| BioStem Technologies, Inc. | -7.77 Million USD | 68.436% |
| LadRx Corporation | -3.82 Million USD | 35.786% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 84.528% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -119.421% |
| CSL Limited | 3.7 Billion USD | 100.066% |
| Biomind Labs Inc. | -1 Million USD | -143.196% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -163.621% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 103.0% |
| Nascent Biotech, Inc. | -2.22 Million USD | -10.11% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 96.58% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 149.958% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 169.359% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -59.846% |
| Marizyme, Inc. | -34.08 Million USD | 92.797% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 70.595% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -334.783% |
| Zenith Capital Corp. | -8.94 Million USD | 72.545% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 13.864% |
| Halberd Corporation | -75.05 Thousand USD | -3171.575% |
| Genus plc | 6.4 Million USD | 138.364% |
| Pharming Group N.V. | -4.87 Million USD | 49.681% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -23.601% |
| IMV Inc. | -38.67 Million USD | 93.651% |
| Affymax, Inc. | -15.04 Million USD | 83.681% |
| SYBLEU INC | -149.18 Thousand USD | -1545.875% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -135.184% |
| Enzolytics Inc. | -2.14 Million USD | -14.265% |
| argenx SE | -425.04 Million USD | 99.422% |
| AVAX Technologies, Inc. | 6.69 Million USD | 136.686% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -75.131% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -83.86% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 34.462% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -9654.934% |
| Cell Source, Inc. | -4.32 Million USD | 43.234% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -408.282% |
| Q BioMed Inc. | -3.44 Million USD | 28.741% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 42.07% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -95.487% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 6.554% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 46.093% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 95.534% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 15.37% |
| Rebus Holdings, Inc. | -664 Thousand USD | -269.777% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -149.511% |
| Skye Bioscience, Inc. | -13.67 Million USD | 82.041% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -31.697% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -22.475% |
| ONE Bio Corp. | 13.68 Million USD | 117.946% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -27.047% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -118.269% |
| Agentix Corp. | -1.37 Million USD | -78.991% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 15.898% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -55.463% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -13994.007% |
| Kadimastem Ltd | -3.04 Million USD | 19.24% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -838.125% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -490.961% |
| NovAccess Global Inc. | -2.46 Million USD | 0.464% |
| Itoco Inc. | -919.14 Thousand USD | -167.132% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1015.658% |
| Qrons Inc. | -643.67 Thousand USD | -281.452% |
| Mobile Lads Corp. | -554.55 Thousand USD | -342.758% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.409% |
| International Stem Cell Corporation | -663 Thousand USD | -270.334% |
| Bioxytran, Inc. | -3.82 Million USD | 35.727% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4564.356% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -11971.372% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 93.23% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -51.75% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -233.678% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 21.076% |
| Neutra Corp. | -229.48 Thousand USD | -969.92% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 86.001% |
| PureTech Health plc | -146.19 Million USD | 98.321% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 88.575% |
| IXICO plc | -1.43 Million USD | -70.864% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 74.13% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.984% |
| CSL Limited | 3.81 Billion USD | 100.064% |
| Cellectis S.A. | -108.85 Million USD | 97.744% |